Impact of age cutoffs on a lynch syndrome screening program

Journal of Oncology Practice

Volumn 9, Issue 4, 2013, Pages 175-179

  Gudgeon, James M ^a   Belnap, Thomas W ^b   Williams, Janet L ^b   Williams, Marc S ^b  

^a Clinical Genetics Institute   (United States)

^b GEISINGER HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER SCREENING; CONFERENCE PAPER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; INTEGRATED HEALTH CARE SYSTEM; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH;

ADULT; AGE FACTORS; AGED; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; EARLY DETECTION OF CANCER; GENETIC TESTING; HUMANS; MASS SCREENING; MIDDLE AGED; PREVALENCE; SENSITIVITY AND SPECIFICITY;

EID: 84887048407     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2012.000573     Document Type: Conference Paper

References (14)

1. Centers for Disease Control and Prevention: United States Cancer Statistics: 1999-2008 incidence and mortality web-based report. 2012. http://www.cdc.gov/uscs
2. Bellcross CA, Bedrosian SR, Daniels E, et al.: Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: Summary of a public health/clinical collaborative meeting. Genet Med 14:152-162, 2012
3. Hampel H, Stephens JA, Pukkala E, et al.: Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: Later age of onset. Gastroenterology 129: 415-421, 2005
4. Lindor NM, Petersen GM, Hadley D.W., et al.: Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: A systematic review. JAMA 296:1507-1517, 2006
5. Palomaki GE, McClain MR, Melillo S, et al.: EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11:42-65, 2009
6. Evaluation of Genomic Applications in Practice and Prevention: Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11:35-41, Jan 2009
7. Mvundura M, Grosse SD, Hampel H, et al.: The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 12:93-104, 2010
8. Ladabaum U, Wang G, Terdiman J., et al.: Strategies to identify the Lynch syndrome among patients with colorectal cancer: A cost-effectiveness analysis. Ann Intern Med 155:69-79, 2011
9. Gudgeon JM, Williams JL, Burt R.W., et al.: Lynch syndrome screening implementation: Business analysis by a healthcare system. Am J Manag Care 17 e288-e300, 2011
10. Hampel H, Frankel WL, Martin E, et al.: Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352:1851-1860, 2005
11. Hampel H, Frankel WL, Martin E, et al.: Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26:5783-5788, 2008
12. Bertagnolli MM, Niedzwiecki D, Compton C.C., et al.: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 27:1814-1821, 2009
13. Ohrling K, Edler D, Hallstrom M., et al.: Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer. Acta Oncol 6:797-804, 2010
14. National Cancer Institute: Cancer of the colon and rectum (invasive). 2004-2008 http://seer.cancer.gov/csr/1975-2008/browse-csr.php?section= 6&page=sect-06-table.23.html.